XML 59 R42.htm IDEA: XBRL DOCUMENT v3.20.4
COMMITMENTS AND CONTINGENCIES (Tables)
12 Months Ended
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contingent Consideration
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the years ended December 31, 2020 and 2019 is as follows (in thousands):

Year Ended December 31, 2020Contingent Consideration Liability Related to Acquisition of Arkis (See Note 5)Contingent Consideration Liability Related to Acquisition of Derma SciencesLocation in Financial Statements
Short-termLong-termLong-term
Balance as of January 1, 2020$— $14,210 $230 
Transfers from long-term to current portion3,415 (3,415)— 
Loss from change in fair value of contingent consideration liabilities — 951 — Research and development
Balance as of December 31, 2020$3,415 $11,746 $230 

Year Ended December 31, 2019Contingent Consideration Related to Acquisition of Arkis (See Note 5)Contingent Consideration Liability Related to Acquisition of Derma SciencesLocation in Financial Statements
Long-termLong-term
Balance as of January 1, 2019$— $230 
Additions from acquisition of Arkis13,100 — 
Loss from change in fair value of contingent consideration liabilities 1,110 — Research and development
Balance as of December 31, 2019$14,210 $230